SCHEMBL21296936

SCHEMBL21296936

O=C(O)c1nn[nH]c1Oc1cccc(-c2cccc(Cl)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 6/20 0.48
PIN1 Q13526 2/20 0.44
XDH P47989 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
MDM2 Q00987 1/20 0.40
KMO O15229 2/20 0.39
LMNA P02545 1/20 0.38
DCLRE1B Q9H816 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
PTPN1 P18031 1/20 0.38
DUSP3 P51452 1/20 0.38
TET3 O43151 1/20 0.37
BBOX1 O75936 1/20 0.37
VEGFA P15692 1/20 0.37
FLT1 P17948 1/20 0.37
ASPH Q12797 1/20 0.37
TET2 Q6N021 1/20 0.37
KDM8 Q8N371 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799241 1.00 HAO1 (0.48) HAO1PIN1XDHSLC22A12MDM2
SCHEMBL29799196 0.94 RXRA (0.46) HAO1PIN1XDHSLC22A12RXRA
SCHEMBL21296934 0.94 RXRA (0.46) HAO1PIN1XDHSLC22A12RXRA
SCHEMBL21312624 0.91 HAO1 (0.47) HAO1PIN1XDHSLC22A12MDM2
SCHEMBL29799238 0.91 HAO1 (0.47) HAO1XDHSLC22A12RXRARXRB
SCHEMBL21296979 0.91 HAO1 (0.47) HAO1XDHSLC22A12RXRARXRB
SCHEMBL29799085 0.90 HAO1 (0.44) HAO1PIN1MRGPRX4RXRARXRB
SCHEMBL21296859 0.90 HAO1 (0.44) HAO1PIN1MRGPRX4RXRARXRB
SCHEMBL21296850 0.88 KMO (0.44) HAO1XDHSLC22A12KMO
SCHEMBL29799107 0.88 KMO (0.44) HAO1XDHSLC22A12KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX HAO1 14/4885PIN1 2801/4885XDH 1/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX HAO1 14/4885PIN1 2801/4885XDH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.